GlassScriptPhysician profile
Ana Marie U Dizon
NPI 1245280114
$9,754.60
in general payments reported to CMS, 2019-2025
31 companies · $1,608 in 2025
The $1,608 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,890 · 2020: $1,269 · 2021: $758 · 2022: $656 · 2023: $229 · 2024: $344 · 2025: $1,608.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,482 · Travel and Lodging: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,481.99 |
| Travel and Lodging | $699.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,588.68 | 2019-2021 | |
| Medtronic, INC. | $1,401.53 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $628.05 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $317.37 | 2019-2025 | Tepezza, Evenity |
| Lilly USA, LLC | $267.84 | 2019-2023 | Mounjaro |
| Abbvie INC. | $218.87 | 2019-2024 | Synthroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $209.42 | 2019-2025 | Jardiance |
| Dexcom, INC. | $173.90 | 2019-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $87.63 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $83.50 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Corcept Therapeutics | $82.86 | 2021-2025 | Korlym |
| Zealand Pharma US, INC. | $76.07 | 2021-2022 | |
| Mannkind Corporation | $66.72 | 2022-2023 | Afrezza |
| Radius Health, INC. | $57.93 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $53.21 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $48.60 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $44.51 | 2021 | |
| Insulet Corporation | $44.41 | 2025 | Omnipod |
| Ibsa Pharma INC. | $41.54 | 2019 | |
| Vistapharm, INC. | $34.61 | 2021 | |
| Horizon Therapeutics Plc | $31.80 | 2021 | |
| Amneal Pharmaceuticals LLC | $29.85 | 2022-2023 | Unithroid |
| Becton, Dickinson and Company | $23.10 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $21.63 | 2021 | |
| Nevro Corp. | $21.37 | 2022 | |
| Sequel Med Tech, LLC | $20.51 | 2025 | Twiist |
| Novartis Pharmaceuticals Corporation | $19.32 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2025 | |
| Intuity Medical INC | $14.93 | 2022 | |
| Clarus Therapeutics INC. | $14.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Marie Dizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.